新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨

doi:10.5246/jcps.2021.08.056

中国药学(英文版) ›› 2021, Vol. 30 ›› Issue (8): 686-691.DOI: 10.5246/jcps.2021.08.056

新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨

武海艳¹, 王涛³, 王倩¹, 唐琳²^,^*()

1. 山东第一医科大学附属中心医院药学部, 山东济南 250013
2. 山东第一医科大学附属省立医院药学部, 山东济南 250021
3. 山东第一医科大学附属中心医院精益项目管理办公室, 山东济南 250013

收稿日期:2020-12-28 修回日期:2021-01-04 接受日期:2021-03-22 出版日期:2021-08-29 发布日期:2021-08-29
通讯作者: 唐琳
作者简介:
+ Tel.: +86-531-68776461, E-mail: lintang1989@126.com

Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal

Haiyan Wu¹, Tao Wang³, Qian Wang¹, Lin Tang²^,^*()

1 Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China
2 Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
3 Department of Lean Project Management, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China

Received:2020-12-28 Revised:2021-01-04 Accepted:2021-03-22 Online:2021-08-29 Published:2021-08-29
Contact: Lin Tang

摘要/Abstract

摘要：

新生儿GBS脑膜炎的临床表现为: 非特异性、住院时间长、易引起神经系统并发症和后遗症。临床药师参与一例停药时脑脊液仍异常的新生儿无乳链球菌脑膜炎的抗感染治疗。根据抗菌药物PK/PD特性、血脑屏障通透性、抗生素的剂量调整, 分析脑脊液细胞数在使用万古霉素治疗后先降低后上升的原因, 分析利奈唑胺治疗新生儿细菌性脑膜炎的疗效, 探讨脑脊液异常时停药的适应症, 以提高新生儿细菌性脑膜炎用药的安全性和有效性。

关键词: 无乳链球菌脑膜炎, 万古霉素, 利奈唑胺, 药物停药指征, 文献分析

Abstract:

The clinical manifestations of neonatal GBS meningitis are as follows: non-specificity, long hospital stay, easy to cause neurological complications, and sequelae. Clinical pharmacist participated in the anti-infective treatment of a neonatal Streptococcus agalactiae meningitis whose cerebrospinal fluid was still abnormal when the drug was stopped. According to the PK/PD characteristics of antibacterial drugs, the permeability of the blood-brain barrier, and the adjustment of the antibiotic dose, the reasons for the decrease in the number of cerebrospinal fluid cells after vancomycin treatment were analyzed. Clinical pharmacists also analyzed the efficacy of linezolid in the treatment of neonatal bacterial meningitis, and discussed the indications for stopping medication when the cerebrospinal fluid is abnormal, so as to improve the safety and effectiveness of antibiotics in the treatment of neonatal bacterial meningitis.

Key words: Streptococcus agalactiae meningitis, Vancomycin, Linezolid, Drug withdrawal indications, Literature analysis

Supporting:

武海艳, 王涛, 王倩, 唐琳. 新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨[J]. 中国药学(英文版), 2021, 30(8): 686-691.

Haiyan Wu, Tao Wang, Qian Wang, Lin Tang. Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 686-691.

图/表 2

参考文献 15

[1]	Maisey, H.C.; Doran, K.S.; Nizet, V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert. Rev. Mol. Med. 2008, 10, e27.
[2]	Zimmermann, P.; Gwee, A.; Curtis, N. The controversial role of breast milk in GBS late-onset disease. J. Infect. 2017, 74, S34–S40.
[3]	Ju, H.Q.; Bei, F.; Sun, J.H. Clinical analyses of 16 neonatal group B streptococcus meningitis cases. Chin. J. Neonatology. 2016, 3, 178–181.
[4]	Chinese expert consensus on clinical application of vancomycin (2011). Chin. J. New. Drugs Clin. Rem. 2011, 8, 561–573.
[5]	Durham, S.H.; Simmons, M.L.; Mulherin, D.W.; Foland, J.A. An evaluation of vancomycin dosing for complicated infections in pediatric patients. Hosp. Pediatr. 2015, 5, 276–281.
[6]	Nau, R.; Sörgel, F.; Eiffert, H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 2010, 23, 858–883.
[7]	Gilbert, D.N. The Sandford Guide to Antimicrobial Therapy 2018(48th Edition). China Union. Medical. Univ. Press. 2018, 95–96.
[8]	Sullins, A.K.; Abdel-Rahman, S.M. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Pediatr. Drugs. 2013, 15, 93–117.
[9]	Di Paolo, A.; Gori, G.; Tascini, C.; Danesi, R.; Del Tacca, M. Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin. Pharmacokinet. 2013, 52, 511–542.
[10]	Chiappini, E.; Conti, C.; Galli, L.; de Martino, M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin. Ther. 2010, 32, 66–88.
[11]	Cao, Y.; Cheng, G.Q.; Hou, X.L.; Jiang, L.; Liu, J.; Liu L.; Tang, Y.N.; Tang, Z.Z.; Tong, X.M.; Xiao, J.X.; Yang, H.X.; Yu, J.L.; Zhou, C.L.; Zhou, W.; Zhou, W.H.; Zhou, X.Y.; Zhang, W. Etiology, diagnosis and treatment of bacterial meningitis in newborns. Chin. J. Perinat. Med. 2016, 2, 881–884.
[12]	Yang, H.H.; Li, J. Clinical and prognostic analysis of sepsis caused by Streptococcus agalactiae combined with purulent meningitis in 12 neonates. J. Clin. Pediatr. 2016, 34, 181–184.
[13]	Subspecialty Group of Neurology, the Society of Pediatrics, Chinese Medical Association. Expert consensus on diagnosis and treatment of community acquired bacterial meningitis in children. Chin. J. Pediatr. 2019, 57, 584–591.
[14]	Jiang, Z.F.; Shen, KL.; Shen, Y. Zhu Futang Practice of pediatrics (8th edition). People’s Medical Publishing House. 2015, 987–989
[15]	Wang, D.; Guo, H.; Jin, J.P.; Wu, C.F.; Liang, C.; Huang, Y.J.; Jin, B.; Lu, H.Y.; Lu, X.P.; Zheng, G. Clinical and cerebrospinal fluid follow-up of 25 cases of community-acquired acute bacterial meningitis with abnormal cerebrospinal fluid at the time of drug withdrawal. J. Nanjing Med. Univ. 2017, 37, 880–881.

新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨

Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 15

相关文章 7

编辑推荐

Metrics

本文评价

[1]	常馨予, 韩丽娟, 刘洋, 范峥, 吴剑坤. 碳青霉烯类药物致血小板不良反应分析及相关文献回顾[J]. 中国药学(英文版), 2023, 32(10): 835-841.
[2]	袁叶, 于博, 杨珍珍, 董维冲, 杨秀岭. 达格列净在血容量不足患者中的药学监护及文献分析[J]. 中国药学(英文版), 2022, 31(9): 718-722.
[3]	裴彦宇, 郝继晖, 段文琪, 郑宇静, 赵明, 杨莉萍. 利奈唑胺严重与致死性不良反应——案例报道的汇总分析[J]. 中国药学(英文版), 2022, 31(2): 153-161.
[4]	吴朝晖, 林慧芬, 林玮玮, 刘亦伟, 游翔, 林翠鸿, 林荣芳, 曾大勇, 黄品芳. 中国成人万古霉素稳态谷浓度与疗效和安全性相关性的前瞻性队列研究[J]. 中国药学(英文版), 2020, 29(5): 341-354.
[5]	张金, 林玮玮, 吴委, 郭仙忠, 黄品芳, 林新华, 焦正, 王长连. 中国老年患者万古霉素群体药动学及个体化给药应用研究[J]. 中国药学(英文版), 2020, 29(4): 260-271.
[6]	张金莲, 周佳, 陈霁晖, 陈婷, 刘艳, 田怀平, 张健. 临床药师对婴幼儿万古霉素血药浓度监测情况分析[J]. 中国药学(英文版), 2015, 24(4): 263-266.
[7]	叶志康, 唐惠林, 段京莉, 翟所迪^*. 非达霉素与万古霉素治疗艰难梭菌感染的有效性和安全性比较: 系统评价和荟萃分析[J]. 中国药学(英文版), 2013, 22(6): 508-515.